YTHDF2 and gastric cancer: Taken together, these data demonstrated that YTHDF2 is down-regulated in gastric cancer, and its expression is negatively correlated with the prognosis and progression of GC patients, implicating that YTHDF2 might act as a prospective biomarker in GC.